Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Dresden – page 57

965 clinical trials in Dresden, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dresden at a glance
965
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

965 trials in Dresden

Open in trial search

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Influenza

Not recruiting

Study of mRNA-1010 Influenza Vaccine Compared to Standard Flu Vaccine in Adults 50 Years and Older

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:CX-037231
  • Sponsor:Moderna Inc.

Multiple system atrophy

Not recruiting

Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Pulmonary hypertension

Not recruiting

Study on Sotatercept for Treating Pulmonary Hypertension in Adults with Heart Failure

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Haematological malignancy+1

Not recruiting

Study of ICT01 and Pembrolizumab for Patients with Advanced-Stage, Relapsed/Refractory Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ICT01
  • Sponsor:Imcheck Therapeutics

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Food allergy

Not recruiting

Study on Long-term Benefits and Safety of DBV712 for Children with Peanut Allergy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Arachis Hypogaea Extract
  • Sponsor:Dbv Technologies

Squamous cell carcinoma of the oral cavity+3

Not recruiting

Study of Pembrolizumab with Lenvatinib after Chemoradiation Treatment in Patients with Locally Advanced Head and Neck Cancer who are PD-L1 Positive

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Universitaet Des Saarlandes

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:CLS12311
  • Sponsor:Cellerys AG

Graft versus host disease+1

Not recruiting

Comparison of Post-Transplant Cyclophosphamide versus Anti-T Lymphocyte Immunoglobulin for Prevention of Graft versus Host Disease in Patients Receiving Unrelated Donor Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:DKMS Group gGmbH

Diabetes mellitus

Not recruiting

Study on the Safety and Effects of VX-264 for Patients with Type 1 Diabetes

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VX-264
  • Sponsor:Vertex Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Dresden

What the registry says about research in the country

01 Respiratory Disease Research

Innovative clinical trials focusing on respiratory infections and preventive treatments, including studies of vaccines against RSV and human metapneumovirus in older adults.

  • Respiratory Syncytial Virus Prevention
  • Chronic Rhinosinusitis Treatment
  • Viral Respiratory Infections

Multiple studies evaluating both therapeutic and preventive approaches for respiratory conditions.

02 Oncology Studies

Comprehensive research into various cancer types, including trials for breast cancer, gastric cancer, and pancreatic cancer treatments.

  • Advanced Cancer Therapeutics
  • Targeted Cancer Treatments
  • Immunotherapy Research

Focus on innovative treatment approaches and combination therapies for various cancer types.

03 Autoimmune Conditions

Studies examining treatments for various autoimmune disorders, including psoriatic arthritis and plaque psoriasis.

  • Inflammatory Disease Management
  • Novel Therapeutic Approaches
  • Chronic Disease Treatment

Investigation of new therapeutic options for patients with autoimmune and inflammatory conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.